Does Retatrutide Cause Hives, Burning or Injection-Site Reactions?
What the retatrutide trial tables, the meta-analysis and the approved tirzepatide labels report on injection-site reactions, hives and hypersensitivity.
Research use only. This page provides scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research. Nothing on this page is a protocol, a recommendation or medical advice.
TL;DR: a hypersensitivity signal, no specific hives or burning rate
The question people actually type: does retatrutide cause hives, burning or reactions at the injection site? [NCT04881760; PMID 39318607] What the published data say: a pooled analysis found more broad-category hypersensitivity with retatrutide, but no statistically significant difference in injection-site reactions [PMID 39318607]. What the available sources do not establish: the available results do not establish a retatrutide-specific hives or local burning rate; the posted registries omit an injection-site row under their reporting thresholds [NCT04881760; NCT04867785]. What research communities report: in the Reddit corpus we track, 678 question posts in 12 months, 21 in the 4 to 12 Sept 2026 window matched the injection-site skin regex. These are reports, not evidence of frequency [internal corpus audit].
What do the retatrutide trial tables report about injection-site reactions?
The posted trial tables contain no injection-site reaction row, but that does not establish that no such events occurred [NCT04881760; NCT04867785]. The phase 2 obesity trial randomized 338 participants and reports adverse events over 52 weeks. Its non-serious-event table uses a threshold of at least 5% in any treatment group. A missing row must be read in that reporting context [NCT04881760, AE module].
The table does include pruritus, rash and sensitive skin, alongside the sensory terms allodynia and hyperaesthesia. Those entries are not labeled as site-specific local burning or hives. Turning a general skin or sensory event into a site-specific diagnosis would change what the registry measured [NCT04881760, otherEvents].
The phase 2 diabetes trial randomized 281 participants, with a 36-week adverse-event window and a 5% reporting threshold. Its posted results contain neither an injection-site nor a hypersensitivity row. Retatrutide has no FDA or EMA authorisation, so there is no approved label or routine post-marketing surveillance dataset to fill that gap [NCT04867785, AE module; FDA and EMA status checked 2026-09-12].
How often are hives and other hypersensitivity events reported?
The pooled retatrutide analysis reports a relative hypersensitivity signal, not an absolute hives rate: RR 3.79, with a 95% confidence interval of 1.20 to 11.96 [Pasqualotto 2024, PMID 39318607]. It combined three placebo-controlled trials with 640 participants, including 510 assigned to retatrutide and 130 to placebo, over 16 to 48 weeks.
For injection-site reactions, the same analysis reported RR 1.12, with a 95% confidence interval of 0.11 to 11.48. The wide interval leaves substantial uncertainty; the nonsignificant comparison is not proof of equal risk. Neither pooled category supplies a specific estimate for burning or urticaria [PMID 39318607].
A PubMed search on 2026-09-12 for retatrutide AND (urticaria OR hives OR angioedema OR anaphylaxis) returned 0 records. That documents the search result, not impossibility of a reaction. A separate search that day for retatrutide AND (injection site reaction OR injection site) returned 1 record, PMID 37385280; its abstract contains no injection-site number, and the supplement was not retrieved.
What do the tirzepatide labels report against placebo?
The approved tirzepatide labels provide the absolute local-reaction rates quoted here, but those rates belong to tirzepatide [ZEPBOUND label, section 6.1; MOUNJARO label, section 6.2]. PeptidesDirect does not sell tirzepatide.
These are the study arms of the cited trials, not an application protocol for research vials.
The Zepbound label's 72-week trial pool reports injection-site reactions in 6% to 8% across active arms versus 2% with placebo. Its pooled term includes bruising, erythema, pruritus, pain and rash at the site. The broader hypersensitivity row reports 5% across active arms versus 3% with placebo [ZEPBOUND label, section 6.1].
The Mounjaro label reports a different trial pool, with these separate categories [MOUNJARO label, section 6.2]:
- Tirzepatide
- 3.2%
- Placebo
- 0.4%
- Tirzepatide
- 3.2%
- Placebo
- 1.7%
That label names urticaria and eczema among sometimes severe hypersensitivity events. Zepbound separately reports severe hypersensitivity in 0.1% versus no placebo participants. These label findings cannot be assigned to retatrutide or used to identify the cause of an individual skin reaction [MOUNJARO label, section 6.2; ZEPBOUND label, section 5.6].
What about a lump, a bruise or a pinpoint bleed?
The registry audit documents no injection-site reaction row in either posted retatrutide results table [NCT04881760; NCT04867785]. Bruising is explicitly included in Zepbound's grouped local-reaction term, so the overall percentage is not a bruising-only rate, much less a rate for lumps or pinpoint bleeding [ZEPBOUND label, section 6.1, footnote d].
In a tirzepatide trial pool, 137 of 5025 antibody-evaluable participants developed injection-site reactions; all were nonserious. Of those participants, 119 belonged to the group with treatment-emergent antidrug antibodies and 18 to the group without them [Mullins 2024, PMID 37700637]. That association does not diagnose a forum photograph or establish the mechanism of a retatrutide complaint.
General medical context
Acute face or throat swelling, breathing difficulty or widespread hives are emergency indications. An individual reaction is a clinician question. This is general medical knowledge, not an assessment of a research material or an application instruction.
Can an old site flare up again, and what is the diluent's part?
Old-site flare-ups are documented in an etanercept case report, while benzyl alcohol has separate contact-allergy evidence; neither establishes a retatrutide mechanism [PMID 17953638; PMID 35080274]. The etanercept report described 2 cases and proposed cellular hypersensitivity. PeptidesDirect does not sell etanercept. A PubMed search on 2026-09-12 for recall injection site reaction AND (GLP-1 OR semaglutide OR tirzepatide OR retatrutide) returned 0 records. There is no human evidence for incretin recall reactions in that search result.
Benzyl alcohol, the preservative in bacteriostatic water, was named Allergen of the Year 2026 to highlight its allergenic potential [Le and Wu 2026, PMID 41649135]. In a patch-test registry, 146 of 70,867 patients, or 0.21%, tested positive. The analysis concluded that sensitization was very rare. These are contact-allergy findings, not human data assigning retatrutide-associated burning to a diluent [Geier 2022, PMID 35080274].
Products mentioned
Published retatrutide certificates comprise 11 batch reports with purity of 99.50% to 99.95% from Janoshik, Freedom Diagnostics and BT Labs; the newest is dated 2026-09-01 [PeptidesDirect lab-report record]. Certificates address identity and purity. They do not establish endotoxin status, sterility or diluent quality, and carry no reaction claim.
Research use only. Retatrutide is supplied strictly for in-vitro research. This page provides scientific background, not a protocol, recommendation or medical advice.
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.
Sources
- ClinicalTrials.gov. Phase 2 obesity posted results, AE module and otherEvents. NCT04881760.
- ClinicalTrials.gov. Phase 2 diabetes posted results, AE module. NCT04867785.
- Pasqualotto, 2024. Pooled analysis of three placebo-controlled retatrutide trials. PMID 39318607; PMC11420505.
- DailyMed, revised 2026-09-02. ZEPBOUND label, sections 6.1 and 5.6. Setid 487cd7e7-434c-4925-99fa-aa80b1cc776b.
- DailyMed, revised 2026-09-02. MOUNJARO label, section 6.2. Setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
- Mullins, 2024. Tirzepatide phase 3 pool, Table 5. PMID 37700637; PMC10795913.
- Gonzalez-Lopez, 2007. Etanercept recall injection-site reactions. PMID 17953638.
- Le and Wu, 2026. Benzyl alcohol, Allergen of the Year 2026. PMID 41649135.
- Geier, 2022. Benzyl alcohol patch-test registry analysis. PMID 35080274.
- PubMed and ClinicalTrials.gov, queried 2026-09-12. Search strings and counts reproduced above; injection-site search abstract record PMID 37385280.
- PeptidesDirect. Published retatrutide batch certificates. https://api.peptidesdirect.io/products/lab-reports
- PeptidesDirect, 2026-09-12. Internal Reddit corpus audit, injection-site skin regex over title and selftext: question-posts.jsonl and delta2/questions.json.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.